Lynparza achieved its goal in a late-stage ovarian cancer trial

assalicon and Mercedon reported positive results for stage 3 PAOLA-1 test Lynparza in women with advanced ovarian cancer.

said the trial evaluated the drug's addition to Standard Care (SoC) beva monoantigen. bevacizumab was used alone in female patients with or without BRCA gene mutations.
The trial reached its primary endpoint in intentional treatment populations, with statistically and clinically significant improvements in progression-free survival (PFS), and women who took Lynparza plus beva monoantia had longer survival times without disease progression or death than those taking beva monotherapy.
the safety and tolerability observed in PAOLA-1 is usually consistent with the known safety and tolerability of each drug, making the study Lynparza's second Phase III positive in advanced ovarian cancer.The positive results of the trial show that "standard treatment for women with advanced ovarian cancer has significant potential benefits," said Jose Baselga, executive vice president of oncology research and development.
He continued, "Based on the positive results of the SOLO-1 test on women with BRCA gene mutations, the PAOLA-1 test marks another positive Phase III clinical trial in Lynparza as a first-line maintenance treatment for women with advanced ovarian cancer." "We look forward to discussing the results with global health authorities as soon as possible."The company announced earlier this month that the drug had also been successful in prostate cancer treatment, after it reached its main endpoint in a Phase III trial of prostate cancer in patients with hrrm recombinant recombinant repair genes, and progressed in previous new hormone anticancer treatments such as Nzarutami and Abitron.
Ovarian cancer is the eighth leading cause of cancer death among women between the world, with nearly 300,000 new cases diagnosed and about 185,000 deaths diagnosed in 2018 alone.
most women are diagnosed with advanced (Stage III or Phase IV) ovarian cancer, with a five-year survival rate of about 30%. （cyy123.com）